<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383693</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A00244-49</org_study_id>
    <nct_id>NCT02383693</nct_id>
  </id_info>
  <brief_title>Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study</brief_title>
  <acronym>TMS/DEP</acronym>
  <official_title>Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de Ville-Evrard, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de Ville-Evrard, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      number of center : 1

        -  duration of study : 24 months

        -  recruitement time : 23 months

        -  Aim :Principal

      Evaluate the interest of maintenance rTMS in a one-year double blind randomized controlled
      study for TRD patients.

      Secondary

      Evaluate the impact of rTMS on cognitive functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study involves 40 TRD patients in a single site trial which consisted of two phases: an
      acute phase (phase I) in which all the participants receive active high-frequency stimulation
      during 4 blocks of five consecutive working days (Monday to Friday) in an open-label design
      and a maintenance phase (phase II) in which responders (&gt; 49% HDRS-17 reduction from
      baseline) at the end of the phase I are randomized in two arms with sham or active
      high-frequency rTMS maintenance treatment for the eleven following months. The rhythm of rTMS
      sessions in this maintenance phase is gradually reduced as follows: 3 sessions per week for 2
      weeks, 2 session per week for the 2 following weeks, 1 session per week the third (M3) and
      fourth month (M4) and then 1 session every fortnight the last eight months (M5 to M12).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>'Hamilton depression rating scale (HDRS)</measure>
    <time_frame>one years</time_frame>
    <description>The efficacy variables included the HDRS-17 item scores, the CGI changes, the Visual Analog Scale (VAS), the Beck Depression Inventory (BDI) and the Hospital Anxiety Depression (HAD).
The subjective assessment performed with the VAS consisted of a 100-mm horizontal line oriented with anchors placed at both poles for reassured, sadness, anxiety, and relief. The patients are asked to mark a spot along this line that best indicated the magnitude of their state for each item.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>repetitive transcranial magnetic stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Repetitive Transcranial Magnetic Stimulation</description>
    <arm_group_label>repetitive transcranial magnetic stimulation</arm_group_label>
    <arm_group_label>Sham comparator</arm_group_label>
    <other_name>TMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TRD stage I Thase-Rush

          -  HDRS + or = 18

          -  Patients age 18 to 70 years.

          -  Negative pregnancy test and contraception for women.

          -  Informed Consent

        Exclusion Criteria:

          -  Patient was treated with mood stabilizer in the previous week

          -  Other disorder on axis I of the DSM IV than depressive disorder.

          -  Patient with an addiction problem other than tobacco and caféine

          -  antécedent of Epilepsy ,other neurological pathology and intra cranial metal
             diapositive or pacemaker

          -  Previous history of head trauma the previous two years.

          -  intracranial hypertension.

          -  not affiliated to the social security Patient

          -  patient under constraint hospitalisation

          -  Under legal protection measure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene BENADHIRA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>E.P.S ville Evrard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique januel, MD.Phd</last_name>
    <phone>0143093232</phone>
    <email>domjanuel@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unité de Recherche Clinique</name>
      <address>
        <city>Neuilly Sur Marne</city>
        <state>Île de France</state>
        <zip>93330</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arezki OURRAD, BIOLOGISTE</last_name>
      <phone>0143093232</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de Ville-Evrard, France</investigator_affiliation>
    <investigator_full_name>René BENADHIRA</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>tolerability</keyword>
  <keyword>efficiency</keyword>
  <keyword>TMS</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

